# Crescent Biopharma

Crescent Biopharma is an Asset Manager based in United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** United States
- **Region:** North America
- **Assets under management:** Undisclosed
- **Website:** https://crescentbiopharma.com
- **LinkedIn:** https://www.linkedin.com/company/crescent-biopharma

## Regulatory record

- **Reports private funds:** No

## About

Crescent Biopharma maintains a deliberately low public profile, consistent with a privately held investment entity focused on a narrow band of biotech opportunities. The firm came into limited public view through a Schedule 13G filing with the US Securities and Exchange Commission, which disclosed a 5.8% beneficial ownership stake in Perspective Therapeutics (ticker: CATX) as of February 2024. Perspective Therapeutics is a clinical-stage company specializing in targeted radionuclide therapies — a subsector of oncology that uses tumor-seeking peptides to deliver radioactive isotopes directly to cancer cells. The filing places Crescent Biopharma as a significant institutional holder alongside other healthcare-dedicated funds. Crescent Biopharma's strategy appears anchored in public-equity biotechnology investing, specifically within the radiopharmaceutical and precision oncology space. Targeted alpha therapy, the mechanism pursued by Perspective Therapeutics, represents an emerging modality distinct from external-beam radiation, attracting dedicated pools of capital seeking to capture a specific technological wave within the broader oncology market. Team composition and total assets remain undisclosed. The firm operates without a known website or LinkedIn presence, a posture more common among single-principal investment offices and holding companies than among multi-client asset managers raising third-party capital. No adjacent philanthropic vehicles or operating subsidiaries have been identified in public filings. The disclosure of a single 13G-position in early 2024 provides the only operational timestamp in the firm's public timeline, and no subsequent activity has been recorded. Crescent Biopharma's structural differentiator is its apparent single-thesis concentration in a subsector — radiopharmaceuticals — that major generalist biotech funds typically access through diversified portfolios.

## Sectors

- Biotechnology

## Questions

### Who manages Crescent Biopharma?

No named principals, executive officers, or investment committee members have been identified in public records. The firm's SEC filings do not disclose individual control persons beyond standard institutional-investor classifications. This opacity is typical of closely held investment vehicles.

### What is Perspective Therapeutics, and why is it relevant to Crescent Biopharma?

Perspective Therapeutics (Nasdaq: CATX) is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies using lead-212 isotopes. Crescent Biopharma's 5.8% ownership stake, disclosed in early 2024, makes it the only known asset in the firm's portfolio, positioning radiopharma as the current center of gravity for its investment thesis.

## Related profiles

- [Rigel Pharmaceuticals](https://altss.com/profile/rigel-pharmaceuticals-inc)
- [Miller Industries](https://altss.com/profile/miller-industries-inc-tn)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/crescent-biopharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology